Association of the G2014G Genotype in Estrogen Receptor 1 Gene with Failure of the Mifepristone-Induced Termination of Early Pregnancy

Ning Wang; Hui Zhao; Weitian Han; Bin He; Shucheng Zhang; Jiedong Wang
January 2010
Tohoku Journal of Experimental Medicine;Jan2010, Vol. 220 Issue 1, p77
Academic Journal
Mifepristone is a synthetic steroid compound that has been applied to terminate early pregnancy for many years. However, about 15% of the women undergo failure in termination of early pregnancy, the causes of which remain largely unknown. We herein selected estrogen receptor 1 gene (ESR1) as a candidate gene to determine whether single nuclear polymorphisms (SNPs) in ESR1 were associated with the failure of mifepristone-induce abortion. The subjects recruited were 30 subjects that failed to abort and 60 subjects with a successful medical abortion. Three SNPs, T-397C (rs2234693), C325G (rs1801132), and G2014A (rs2228480), were analyzed by PCR, followed by restriction fragment length polymorphism (RFLP) analysis. The latter two polymorphic sites are located in the protein-coding region, but do not alter the amino acid. Among the three SNPs examined, we found the significant role of the G2014A polymorphism; namely, the distribution of the GG, AG and AA genotypes was different between the failure group and the success group. The frequency of the GG (G2014G) genotype was higher in the failure group (86.7%) than that in the success group (60.0%) (p = 0.030), while the frequency of the G2014A heterozygote was lower in the failure group (6.7%) than in the success group (28.3%) (p = 0.013). Moreover, the frequency of the G allele was higher in the failure group (90%) and lower in the success group (10.0%) (p = 0.013). These results indicate that the GG genotype of the G2014A polymorphism is associated with the risk of failure in the mifepristone-induced abortion.


Related Articles

  • Pregnancy termination.  // Australian Journal of Pharmacy;Mar2013, Vol. 94 Issue 1114, p34 

    The article presents information on medical termination of pregnancy by using a synthetic steroid Mifepristone.

  • The abortion choices. Sweet, Melissa // Bulletin with Newsweek;10/31/2000, Vol. 118 Issue 6248, p44 

    Reveals the widespread use of non-abortifacient medicines to induce medical abortions in Australia. Lack of access to medical abortion via mifepristone; Lower success rate of cancer and rheumatoid arthritis drug methotrexate in inducing abortion; Women's avoidance of surgical abortion due to...

  • Abortifacient development should not be stifled. Dahm, Diane; Dahm, D // JAMA: Journal of the American Medical Association;10/6/89, Vol. 262 Issue 13, p1876 

    Reports on the development of the progesterone antagonist RU-486 (mifepristone), a synthetic antiprogestin that works by competitive inhibition at the receptor level in both the endometrium and trophoblast. Induction of complete abortion in women when administered with a subtherapeutic dose of...

  • The safest way to abort.  // Prevention India;Jul2011, p2 

    The article offers information on the safe way for the medical termination of pregnancy through abortion pills, and the medication for a bee sting. It informs that pregnancy up to 49 days gestation can be aborted by taking two drugs, Mifegest (mifepristone) and Cytolog (misoprostol). It further...

  • French Trials of RU 486 find 96 Percent Abortion Rate in Pregnancies of Less Than Seven Weeks. Klitsch, M. // Family Planning Perspectives;May/Jun90, Vol. 22 Issue 3, p134 

    The article presents a discussion on clinical trials of the antiprogestin mifepristone (RU 486) drug in France. Abortion can be induced without surgery at least 96 percent of the time when the RU 486 drug is given, along with a prostaglandin, to women pregnant for less than seven weeks,...

  • Comparison of two doses and two routes of administration of misoprostol after pre-treatment with mifepristone for early pregnancy termination. von Hertzen, Helena; Piaggio, Gilda; Marions, Lena // Reproductive Health;2008, Vol. 5, Special section p1 

    Background: It is not known whether a 400 �g dose of misoprostol has a similar efficacy as an 800 �g dose when administered sublingually or vaginally 24 hours after 200 mg mifepristone. Methods: It is proposed to undertake a placebo-controlled, randomized, non-inferiority trial (3%...

  • Septic shock after medical abortions with mifepristone (Mifeprex, RU 486) and misoprostol. Murray, Sally; Wooltorton, Eric // CMAJ: Canadian Medical Association Journal;8/30/2005, Vol. 173 Issue 5, p485 

    Deals with septic shock after medical abortions with mifepristone and misoprostol. Other medical conditions where the drugs are used; Organisms causing septic shock; Ways of preventing septic shock.

  • RU-4-chemical abortion? Rogers, David // Alberta Report / Newsmagazine;03/29/99, Vol. 26 Issue 14, p29 

    Focuses on the abortion pill RU-486 and efforts by British Columbia Health Minister Penny Priddy to make it available in Canada. Correspondence by Health Canada to the manufacturer of RU-486 in March 1999; Priddy's public support of the abortion pill; Why the drug developer has no plans to...

  • Attributes and perspectives of public providers related to provision of medical abortion at public health facilities in Vietnam: a cross-sectional study in three provinces. Ngo, Thoai D.; Free, Caroline; Le, Hoan T.; Edwards, Phil; Pham, Kiet H. T.; Nguyen, Yen B. T.; Nguyen, Thang H. // International Journal of Women's Health;2014, Vol. 6, p789 

    Background: The purpose of this study was to investigate attributes of public service providers associated with the provision of medical abortion in Vietnam. Methods: We conducted a cross-sectional study via interviewer-administered questionnaire among abortion providers from public health...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics